1.87
-0.14(-6.97%)
Currency In USD
| Previous Close | 2.01 |
| Open | 1.99 |
| Day High | 2.03 |
| Day Low | 1.86 |
| 52-Week High | 2.16 |
| 52-Week Low | 0.65 |
| Volume | 364,520 |
| Average Volume | 316,337 |
| Market Cap | 112.03M |
| PE | -0.99 |
| EPS | -1.88 |
| Moving Average 50 Days | 1.5 |
| Moving Average 200 Days | 1.15 |
| Change | -0.14 |
If you invested $1000 in Opus Genetics, Inc. (IRD) since IPO date, it would be worth $23,375 as of October 18, 2025 at a share price of $1.87. Whereas If you bought $1000 worth of Opus Genetics, Inc. (IRD) shares 1 year ago, it would be worth $1,449.61 as of October 18, 2025 at a share price of $1.87.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference
GlobeNewswire Inc.
Oct 14, 2025 12:00 PM GMT
RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseas
Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025
GlobeNewswire Inc.
Oct 02, 2025 12:00 PM GMT
RESEARCH TRIANGLE PARK, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therap
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
GlobeNewswire Inc.
Sep 30, 2025 11:00 AM GMT
Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicitiesLasting, durable responses observed out to 18 months in adult participantsExpecte